PMID- 29390494
OWN - NLM
STAT- MEDLINE
DCOM- 20180220
LR  - 20221207
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 51
DP  - 2017 Dec
TI  - A possible synergistic effect of MTHFR C677T polymorphism on homocysteine level 
      variations increased risk for ischemic stroke.
PG  - e9300
LID - 10.1097/MD.0000000000009300 [doi]
LID - e9300
AB  - BACKGROUND: Homocysteine (Hcy) plays an important role in vascular function and 
      Hcy level contributes to pathogenesis of ischemic stroke (IS). MTHFR gene 
      polymorphism may have effects on IS risks by influencing the Hcy metabolic 
      pathway. In the present study, a case-control study was designed to evaluate the 
      relationship among MTHFR C677Tpolymorphism, plasma Hcy level, and susceptibility 
      of IS in Chinese population. METHODS: A total of 300 patients with IS and 261 
      matched control subjects were recruited. Plasma Hcy concentration was determined 
      using enzymatic cycling assay. MTHFR C677T polymorphisms were genotyped by 
      PCR-RFLP. RESULTS: Compared with controls, the plasma Hcy level was significantly 
      higher in the IS patients (P < .05). After adjusting for conventional risk 
      factors, the T allele frequency of MTHFR C677T in IS group (54%) was 
      significantly higher than that in the controls (38.3%) (P < .05; OR = 1.890, 95% 
      CI: 1.489-2.399). Additionally, the plasma Hcy level of the TT genotype is 
      significantly higher than that of the CC and CT genotypes (P < .05). CONCLUSION: 
      Our study provided evidence that hyperhomocysteinemia (HHcy) and MTHFR C677T 
      polymorphism were associated with IS. More importantly, suggesting that a 
      possible synergistic effect of MTHFR C677T polymorphism on Hcy level variations 
      increased risk for IS in Chinese population.
CI  - Copyright (c) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All rights 
      reserved.
FAU - Li, Aifan
AU  - Li A
AD  - Department of Neurology, The First People's Hospital of Zhengzhou Department of 
      Oncology, the First Affiliated Hospital Department of Medical Genetics and Cell 
      Biology, School of Basic Medical Sciences, Zhengzhou University Department of 
      Eugenic Genetics, The First People's Hospital of Zhengzhou Department of 
      Neurology, the First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, 
      China.
FAU - Shi, Yunshu
AU  - Shi Y
FAU - Xu, Liyan
AU  - Xu L
FAU - Zhang, Yuchao
AU  - Zhang Y
FAU - Zhao, Huiling
AU  - Zhao H
FAU - Li, Qiangmin
AU  - Li Q
FAU - Zhao, Xingjuan
AU  - Zhao X
FAU - Cao, Xinhui
AU  - Cao X
FAU - Zheng, Hong
AU  - Zheng H
FAU - He, Ying
AU  - He Y
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Biomarkers)
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - EC 1.5.1.20 (MTHFR protein, human)
RN  - EC 1.5.1.20 (Methylenetetrahydrofolate Reductase (NADPH2))
SB  - IM
MH  - Asian People
MH  - Biomarkers/blood
MH  - Case-Control Studies
MH  - China
MH  - Female
MH  - Gene Frequency
MH  - Genotype
MH  - Homocysteine/*blood
MH  - Humans
MH  - Male
MH  - Methylenetetrahydrofolate Reductase (NADPH2)/*genetics
MH  - Middle Aged
MH  - *Polymorphism, Genetic
MH  - Stroke/blood/*genetics
PMC - PMC5758196
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2018/02/03 06:00
MHDA- 2018/02/21 06:00
PMCR- 2017/12/22
CRDT- 2018/02/03 06:00
PHST- 2018/02/03 06:00 [entrez]
PHST- 2018/02/03 06:00 [pubmed]
PHST- 2018/02/21 06:00 [medline]
PHST- 2017/12/22 00:00 [pmc-release]
AID - 00005792-201712220-00081 [pii]
AID - MD-D-17-06196 [pii]
AID - 10.1097/MD.0000000000009300 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Dec;96(51):e9300. doi: 10.1097/MD.0000000000009300.